KAT2B and lung adenocarcinoma: A study reported that in lung adenocarcinoma tumor growth was compromised in PCAF−/− mice, with reduced infiltration of CD4+Foxp3+ Treg cells but increased infiltration of host CD8 T cells, indicating that targeting PCAF reduces tumor volume and improves anti-tumor immunity (Liu Y. et al., 2019).